Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


BRCA2 and RB1 loss responds to PARP inhibitors


Molecular mechanisms and genomic consequences of BRCA2 and RB1 co-loss were prospectively investigated in prostate cancer cell lines. CRISPR–Cas9 and RNA interference (RNAi) methods were used to eliminate these genes in LNCaP and LAPC4 cells. Loss of BRCA2 led to a castration-resistant phenotype; co-loss of both genes induced epithelial-to-mesenchymal transition (EMT). However, PARP inhibitors attenuated cell growth in human metastatic castration-resistant prostate cancer (CRPC) organoids and CRPC cells that had single-copy loss of both genes. Thus, identification of patients with co-loss of RB1 and BRCA2 could enable early use of PARP inhibition and improve outcomes.


Original article

  1. Chakraborty, G. et al. Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression. Clin. Cancer Res. (2020)

    Article  Google Scholar 

Related article

  1. Taylor, R. A. et al. The influence of BRCA2 mutation on localized prostate cancer. Nat. Rev. Urol. 16, 281–290 (2019)

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Annette Fenner.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fenner, A. BRCA2 and RB1 loss responds to PARP inhibitors. Nat Rev Urol 17, 132 (2020).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing